(Total Views: 563)
Posted On: 03/01/2022 6:55:14 PM
Post# of 22465
Snark, could not have said it better:
"Steve continues to be as solid and resolute in the pursuit of his vision for QMC and for bringing value to shareholders as before. There is no empirical evidence to the contrary."
All his deals since 2016 have been license and royalties, or partnerships, all with no QMC cash upfront, designed to enable QMC to share the value of the unique quantum dots in the end product. The risk is on the partner who also gains from lower upfront and startup costs of materials. Now in the biomed field, QMC seems to be taking it's IP to the product invention and development stages and selling developed products.
It's my opinion and speculation in support of Snark's post.
"Steve continues to be as solid and resolute in the pursuit of his vision for QMC and for bringing value to shareholders as before. There is no empirical evidence to the contrary."
All his deals since 2016 have been license and royalties, or partnerships, all with no QMC cash upfront, designed to enable QMC to share the value of the unique quantum dots in the end product. The risk is on the partner who also gains from lower upfront and startup costs of materials. Now in the biomed field, QMC seems to be taking it's IP to the product invention and development stages and selling developed products.
It's my opinion and speculation in support of Snark's post.
(0)
(0)
